Sanofi, backed by funds awarded by BARDA, broke ground on a new formulation and filling facility at its Swiftwater, Pennsylvania site.
The new formulation and filling facility will be a two-story building complete with CGMP formulation, filling and support areas. The filler will be capable of filling syringe and vials using isolator barrier technology and single-use technology for flexibility.
The facility is one of three significant manufacturing investments made at the site — all supported by federal funds —as part of a $226 million contract awarded back in December 2019 by the Biomedical Advanced Research and Development Authority to increase domestic production capabilities for recombinant pandemic influenza vaccine.
The Sanofi-BARDA contract supports the clinical development of an adjuvanted recombinant pandemic influenza vaccine that utilizes the same technology as Sanofi's recombinant quadrivalent influenza vaccine. The contract also expands the Swiftwater site's capacity to be a center of excellence for pandemic preparedness by enhancing vaccine manufacturing, adding both recombinant and adjuvant technologies to the current egg-based platform capabilities.
Sanofi Pasteur has had operations at the Swiftwater site for125 years. It is currently a 500-acre, 50+ building production facility campus.
